期刊
RSC ADVANCES
卷 7, 期 77, 页码 48561-48568出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7ra08971f
关键词
-
资金
- NIH [K25EB017222, R21CA212851]
- Cancer Prevention and Research Institute of Texas (CPRIT) grant [RR150010]
- Radiological Society of North America Presidents Circle Research Resident Grant [1472]
- [NCI-5R25CA153915-03]
- [T32-EB005970]
- NATIONAL CANCER INSTITUTE [R21CA212851, R25CA153915] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [K25EB017222, T32EB005970] Funding Source: NIH RePORTER
Microbubble (MB) contrast agents have positively impacted the clinical ultrasound (US) community worldwide. Their use in molecular US imaging applications has been hindered by their limited distribution to the vascular space. Acoustic droplet vaporization (ADV) of nanoscale superheated perfluorocarbon nanodroplets (NDs) demonstrates potential as an extravascular contrast agent that could facilitate US-based molecular theranostic applications. However these agents are metastable and difficult to manufacture with high yields. Here, we report a new formulation technique that yields reliable, narrowly dispersed sub-300 nm decafluorobutane (DFB) or octafluoropropane (OFP)-filled phospholipid-coated NDs that are stable at body temperature, using small volume microfluidization. Final droplet concentration was high for DFB and lower for OFP (>10(12) vs. >10(10) NDs per mL). Superheated ND stability was quantified using tunable resistive pulse sensing (TRPS) and dynamic light scattering (DLS). DFB NDs were stable for at least 2 hours at body temperature (37 degrees C) without spontaneous vaporization. These NDs are activatable in vitro when exposed to diagnostic US pressures delivered by a clinical system to become visible microbubbles. The DFB NDs were sufficiently stable to allow their processing into functionalized NDs with anti-epithelial cell adhesion molecule (EpCAM) antibodies to target EpCAM positive cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据